Floatz logo

Dulaglutide

Hyperglycemia

Emory Universityprotein_peptidePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Hyperglycemia cohort.

Asset / SponsorPhaseRating
Metformin
The First Affiliated Hospital of Xiamen University
Phase 4BBB
Olanzapine
Washington University School of Medicine
Phase 4BB
Saffron
Birjand University of Medical Sciences
Phase 4BB
Sitagliptin
Dawn Smiley MD
Phase 4BB
Exenatide
Saint Luke's Health System
Phase 4BB

View all 34 →

Same molecule, other indications

Dulaglutide is also rated in:

glucose intoleranceActive
BBB
Indicative · Phase 4
75 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseActive
BB
Indicative · Phase 4
65 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →